Behcet′s disease is a variable vasculitis characterized by oral aphthous ulcers, ocular lesions and genital ulcers with involvement of arteries, veins, joints, gastrointestinal tract and nerves, resulting in reduced quality of life and even death. The lack of laboratory diagnostic markers for Behcet′s disease, necessitates the identification of biomarkers that correlate with disease phenotype, activity and severity. These biomarkers are crucial for advanced warning, treatment response, monitoring and prognosis assessment. This article reviews recent advances in clinical research on biomarkers for Behcet′s disease, clarifies the role of each biomarker in the pathogenesis of Behcet′s disease, and provides corresponding prospects for future research directions.

Systemic lupus erythematosus (SLE), commonly seen in clinical cases, is a systemic inflammatory disease of connective tissue, which involves multiple systems and organs. It is mainly characterized by a wide range of clinical complications, such as lupus nephritis, neuropsychiatric lupus, and SLE-related cardiovascular events, however, the pathogenesis of SLE has not yet been elucidated. Early diagnosis is of great significance in estimating the severity of SLE, disease activity, predicting relevant progression, supervising therapeutic effects, as well as, improving prognosis. This review will mainly focus on the research advances in clinical application of auto-antibodies and biomarkers previously and recently discovered in patients who has been suffered from SLE.